What's fueling the biotech engine—2011 to 2012
- 7 December 2012
- journal article
- research article
- Published by Springer Nature in Nature Biotechnology
- Vol. 30 (12) , 1191-1197
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell LymphomaClinical Cancer Research, 2012
- Bevacizumab in the Treatment of Ovarian CancerAdvances in Therapy, 2012
- Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative ColitisNew England Journal of Medicine, 2012
- Tofacitinib or Adalimumab versus Placebo in Rheumatoid ArthritisNew England Journal of Medicine, 2012
- What's fueling the biotech engine—2010 to 2011Nature Biotechnology, 2011
- Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritisNature Biotechnology, 2011
- Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trialThe Lancet, 2011
- What's fueling the biotech engine—2009–2010Nature Biotechnology, 2010
- Is Maintenance Rituximab Now Ready for PRIMA-Time?Current Oncology Reports, 2010
- What's fueling the biotech engine—2008Nature Biotechnology, 2009